Healthcare Industry News: Dermal Filler
News Release - March 14, 2012
KYTHERA Biopharmaceuticals Appoints Industry Veteran Elisabeth Sandoval as Chief Commercial OfficerLOS ANGELES--(Healthcare Sales & Marketing Network)--KYTHERA Biopharmaceuticals, Inc. (KYTHERA), a privately-held biotechnology company focused on the development and commercialization of prescription products in aesthetic medicine, today announced the appointment of Elisabeth Sandoval as Chief Commercial Officer.
Elisabeth brings more than 25 years of pharmaceutical and medical device experience to KYTHERA. She spent more than 20 years at Allergan, where she held roles of increasing responsibility that spanned from research and development to sales and marketing. Her tenure at Allergan included the role of Vice President of Global Strategic Marketing for Allergan Medical where she built a high performance marketing team and drove the launch of JUVÉDERM®, the market-leading Dermal Filler, and led the global marketing team for BOTOX® Cosmetic, LATISSE®, Natrelle® breast implants and LAP-BAND®1. Her extensive aesthetic marketing leadership expertise is grounded by early career experience in Field Sales Management and as a Clinical Research Associate. Elisabeth joins KYTHERA from Bausch + Lomb Surgical where she most recently served as Vice President, Global Marketing & Strategy. She began her career in research and development at Johnson & Johnson’s Ethicon division. Elisabeth earned a BS in Biology from the University of California, Irvine, and an MBA from Pepperdine University.
“Elisabeth’s depth of aesthetics industry experience coupled with her proven leadership in marketing strategy and execution make her ideally suited to lead the KYTHERA commercial team,” said Keith Leonard, KYTHERA’s President and CEO. “We hope our continued clinical investigation of ATX-101 will ultimately lead to a safe, effective and approved treatment for the reduction of facial fat under the chin, known as submental fat. We are excited to welcome Elisabeth to KYTHERA, and are confident she will be a valuable addition to our already strong management team.”
About KYTHERA Biopharmaceuticals, Inc.
KYTHERA Biopharmaceuticals, Inc. is a privately held, clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic market. KYTHERA’s lead clinical program, ATX-101, is focused on the reduction of submental (under the chin) fat. The company also has active research programs with focused interest in hair and fat biology, pigmentation modulation and facial contouring. Find more information at www.kytherabiopharma.com.
1 JUVÉDERM®, BOTOX® Cosmetic, LATISSE®, Natrelle® breast aesthetics and LAP-BAND® are registered trademarks of Allergan, Inc.
Source: KYTHERA Biopharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.